CRNX Crinetics Pharmaceuticals (CRNX) Q1 FY26 earnings call
Crinetics Pharmaceuticals reported strong Q1 FY26 results, driven by significant momentum in the Palsonify launch, marked by increasing patient enrollments, expanding prescriber base, and robust reimbursement progress. The company also highlighted substantial advancements across its deep clinical pipeline and a strong financial position, providing a long runway for continued growth and innovation. International regulatory milestones for Palsonify further underscore its global potential.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CRNX operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | This call Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|
| Enrollment forms received | 200+As we previously shared, in Q4, we received more than 200 enrollment forms.Source: earnings call transcript | 232As Scott mentioned, in the first quarter alone, we secured 232 new patient enrollment forms.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.